Conformis, Inc. | August 02, 2022
Conformis, Inc. a leading medical device company that features personalized knee and hip replacement products, announced it has entered into a multi-year agreement with Vizient, Inc., the nation's largest member-driven health care performance improvement company.
“We are excited to offer personalized orthopedic implants to Vizient’s large membership of healthcare facilities through this contract. As more orthopedic patients and surgeons seek personalized solutions, increased awareness and ease of access to our product portfolio is more important than ever. The Vizient agreement connects us to a significant number of providers, many of which have limited access and awareness of our products and our new Platinum Services Program,”
Mark Augusti, Chief Executive Officer and President of Conformis
The agreement gives increased access to the entire Conformis knee and hip portfolio to Vizient’s membership base, which is comprised of academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute health care providers, and includes
Identity Imprint™, a personalized knee replacement system;
Image-to-Implant® Platinum Services Program, a patient-elected deluxe upgrade option to obtain a fully personalized knee replacement implant; and,
Cordera™ Match Hip System, a personalized primary hip replacement solution.
Conformis implants improve efficiency and reduce overall costs for medical facilities. Researchers at the University of Washington in Seattle found that fully personalized total knee arthroplasty is cost-effective in comparison to a standard, off-the-shelf implant. Ongoing research suggests that fully personalized implants further reduce total costs to the healthcare system because patients recover more quickly and are less likely to require follow-up corrective surgeries.
About Conformis, Inc.
Founded in 2004, Conformis is a medical technology company focused on advancing orthopedic patient care and creating a world without joint pain. Its product portfolio is designed to maximize surgeon and patient choice by offering fully personalized solutions through its Image-to-Implant® Platinum Services℠ Program as well as data-informed, standardized solutions that combine many benefits of personalization with the convenience and flexibility of an off-the-shelf system. Conformis’ sterile, just-in-time, Surgery-in-a-Box™ delivery system is available with all of its implants and personalized, single-use instruments. Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints.
Axenya Holdings Inc | August 04, 2022
AXENYA, a leading Latin-American digital health start-up company, and HealthCo, a premier data-intensive consulting firm and insurance broker, announce that they have reached an agreement to merge the companies into the leading corporate health-tech ecosystem in the Latin-American region.
The combined companies will serve over 35,000 lives and have the capacity to deliver value across the entire healthcare journey. The companies expect to more than double that number in the coming year. All founding and operating teams at HealthCo and Axenya will remain in the company and as shareholders of the new company, which will operate under the Axenya brand.
"The New Axenya marries the most advanced population data science with cutting edge, clinically proven, digital therapeutics", said Mariano García-Valiño, Founder of Axenya. "The combination creates an unbeatable ecosystem, where we can gather data to analyze large populations, identify care gaps and create perfectly targeted individual digital plans for each person, improving clinical metrics and reducing cost across the entire spectrum".
Axenya, that started operations in 2020, offers software and hardware products that expand the doctor's toolbox, allows them to help their patients achieve higher standards of health and make the overall practice of medicine more personalized and precise. The company is the first member of the Digital Therapeutic Alliance in Latin America and the only company in the region with clinical research published in peer-reviewed journals. HealthCo is one of the most advanced data-intensive healthcare brokers in the region and approaching 90 corporate clients. Their proprietary data analytics result in consistent savings for their client base.
The combination becomes a one stop shop to enable corporate clients to maximize quality and expense in all aspects of their healthcare needs: from population analytics, 24/7 monitoring and course correction, delivering individually selected next generation digital therapeutic tools and ultimately renegotiating fees with payors driven by the savings generated by its healthcare program. As a result, Axenya will deliver unparalleled clinical results, user satisfaction and cost savings.
"We now have a company that can deliver results like nobody else in the market. Using a combination of software, technology, machine learning and behavioral and data science, Axenya can optimize the healthcare journey end-to-end, empowering companies and its employees with unbiased information, trusted guidance and high-value care, and delivering, at the same time, effective cost savings."
Roberto Vianna, co-Founder of HealthCo
In combination with this merger, Axenya received a capital injection, led by IGAH ventures, and with participation of NXTP, Big_Bets, Alexia, Axenya's founder Mariano Garcia-Valiño and several individual investors and employees.
Axenya is a health technology company that seeks to connect Latin America with the future of medicine. With its digitally enhanced corporate health ecosystem, it offers and manages the most suitable healthcare plans in a digital, efficient and transparent fashion, protecting the employee's health, end to end, through all the journey. Integrating cutting edge software, hardware, artificial intelligence, intensive data-analysis and behavioral sciences, Axenya improves the efficiency in delivering health services, as well as expands the companies' toolbox and makes medicine more personal and precise, offering what is effectively a new care standard. The company delivers excellent patient satisfaction, superior clinic results and lower costs, improving the quality per dollar spent by companies while allowing access to modern medicine to all employees and dependents.
MCI Onehealth Technologies, Inc. | July 29, 2022
MCI Onehealth Technologies Inc. a clinician-led healthcare technology company focused on increasing access to and quality of healthcare, and MDClone, a digital health company and leader in synthetic data, are pleased to announce an advanced clinical intelligence offering for their global partners. This offering combines real-world health insights with mirrored synthetic data to power deeper research and inspire novel therapeutic development.
“MCI’s collaboration with MDClone will provide our partners with greater access to high-value data-insights-as-a-service for an array of research, clinical and data science needs. Whether through MCI’s clinic network, international healthcare providers, or pharmaceutical, life sciences and biotech partners, our mutually enhanced insights will help to quickly translate healthcare data and research into improved health and quality of life for patients.”
Dr. Alexander Dobranowski, MD, Chief Executive Officer of MCI
The real-world patient health journeys that MCI’s tech-enabled network is able to capture offer a comprehensive picture to researchers, who can benefit from a fuller perspective. The partnership between MCI and MDClone will leverage MDClone’s technology to load, organize and protect MCI-generated patient data and use this data to help find insights to improve care. In addition, MCI and MDClone intend to work together to improve data collection and curation to better serve the needs of applied healthcare research.
MDClone offers clients robust, detailed data for thorough end-to-end, real-world analysis. Using the MDClone ADAMS Platform analytics tools and synthetic data capabilities, clinicians, researchers, and healthcare professionals can explore healthcare data more efficiently to accelerate real-world evidence processes. With synthetic data capabilities at the forefront, users can leverage self-service tools to access, analyze, and share information without privacy concerns. Additionally, the real-time identification and extraction of information about a specific population of interest allows users at healthcare systems to overcome some of the common barriers that can slow clinical data projects’ progress.
“We’re thrilled to partner with innovators like MCI in the healthcare and life science industries and beyond. Together, we can provide tailored clinical insights that meet clients’ needs, and from those insights, MDClone can generate synthetic data that researchers can use to better understand disease progression, enhance care delivery, and develop new products that can improve patient outcomes,” said Josh Rubel, Chief Operating Officer of MDClone.
In keeping with its objective to be a preeminent health technology leader, MCI nurtures international opportunities to leverage its vast pool of high-quality structured clinical information. The MDClone ADAMS Platform’s unique ability to convert datasets and cohorts of interest into synthetic files that are statistically comparable to the original data, but composed entirely of artificial patients, aids in broader and more secure access and opens the doors to third-party access and larger-scale research impact.
MCI’s audience for health insights continues to grow in Canada and will further benefit from access to MDClone’s global roster of top-tier health system and pharma relationships. The collaboration with MDClone will accelerate MCI’s entry into the clinical insights and analytics sectors in the United States of America and Israel, including potential access to headquarter-level decision-makers of global pharma and life science leaders.
“Through this commercial arrangement, we each have the benefit of immediate introduction to the active client rosters of the other, and we each gain a superior — and unique — offering to acquire new partners, fueling the expansion of MCI’s health insight services into international markets,” added Dr. Dobranowski.
MCI is a healthcare technology company focused on empowering patients and doctors with advanced technologies to increase access, improve quality, and reduce healthcare costs. As part of the healthcare community for over 30 years, MCI operates one of Canada’s leading primary care networks with nearly 260 physicians and specialists, serves more than one million patients annually and had nearly 300,000 telehealth visits last year, including online visits via mciconnect.ca. MCI additionally offers an expanding suite of occupational health service offerings that support a growing list of nearly 600 corporate customers. Led by a proven management team of doctors and experienced executives, MCI remains focused on executing a strategy centered around acquiring technology and health services that complement the company’s current roadmap.
MDClone offers an innovative, self-service data analytics environment powering exploration, discovery, and collaboration throughout healthcare ecosystems cross-institutionally and globally. The powerful underlying infrastructure of the MDClone ADAMS Platform allows users to overcome common barriers in healthcare in order to organize, access, and protect the privacy of patient data while accelerating research, improving operations and quality, and driving innovation to deliver better patient outcomes. Founded in Israel in 2016, MDClone serves major health systems, payers, and life science customers in the United States, Canada, and Israel.